Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

CD38 Overexpressed Monocytes Play a Critical Role in the Fibrogenesis in Myeloproliferative Neoplasms and Can be Used As a Therapeutic Target to Ameliorate Fibrosis

Yiru Yan, Jinqin Liu, Lin Yang, Gang Huang, Xiaofan Zhu, Raajit Rampal, Zhijian Xiao, Bing Li

Blood (2024) 144 (Supplement 1): 874.

https://doi.org/10.1182/blood-2024-202529

Published: 2024

Journal Articles

The Implication of TP53 Allelic Status for Outcome and Erythropoiesis in MDS

Bing Li, Yanping Zeng, Chengwen Li, Jinqin Liu, Ge Song, Yao Yao, Amer M. Zeidan, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6707.

https://doi.org/10.1182/blood-2024-205429

Published: 2024

Journal Articles

GATA1 Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

Fuhui Li, Yudi Zhang, Chengwen Li, Qi Sun, Jinqin Liu, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Lijuan Pan, Qingyan Gao, Meng Jiao, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6734.

https://doi.org/10.1182/blood-2024-200761

Published: 2024

Journal Articles

Impact of the 15-Item Frailty Scale in IPSS-R/IPSS-M Subgroup of Patients (Pts) with Myelodysplastic Syndromes (MDS)

Xin Wang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Bing Li, Li Juan Pan, Qingyan Gao, Meng Jiao, Jinying Zhao, Wenjun Xie, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6729.

https://doi.org/10.1182/blood-2024-199104

Published: 2024

Journal Articles

A Correlation of Ineffective Erythropoiesis and Dysregulated Pathways in Myelodysplastic Syndromes

Junying Wu, Jinqin Liu, Lin Yang, Bing Li, Chen Jia, Fuhui Li, Robert Peter Gale, Zhi-jian Xiao

Blood (2024) 144 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2024-201427

Published: 2024

Journal Articles

Aberrant Splicing in CHEK1 Is a Driver of Megakaryocytic Dysplasia in U2AF1 S34F Mutant Myelodysplastic Syndromes

Wenjun Zhang, Jinqin Liu, Gang Huang, Zhijian Xiao, Bing Li

Blood (2024) 144 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2024-200825

Published: 2024

Journal Articles

Construction and Verification of Prediction Model of Frailty Risk in Elderly Patients with Hematological Neoplasms

Jinying Zhao, Zhang Qianqian, Yating Liu, Bing Li, Wenjun Xie, Erlie Jiang, Xin Wang

Blood (2024) 144 (Supplement 1): 7943.

https://doi.org/10.1182/blood-2024-206404

Published: 2024

Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Yan Lu, Shaoguang Li, Aibin Liang

Blood (2024) 144 (Supplement 1): 6524.

https://doi.org/10.1182/blood-2024-208414

Published: 2024

Journal Articles

An Open-Label, Multicenter, Phase Ib Study of the Anti-TIM3 Monoclonal Antibody BC3402 in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Bing Li, Qing-song Yin, Xiaojing Yan, Min Hang, Hai-Jun Guo, Sheng Wang, Yi-wei Wang, Yong-jiang Hei, Zhi-jian Xiao

Blood (2024) 144 (Supplement 1): 4135.

https://doi.org/10.1182/blood-2024-201319

Published: 2024

Journal Articles

Factors Associated with Progression to Overt Acute Myeloid Leukemia in NPM1 -Mutated Myeloid Neoplasms with Less Than 10% Blasts

Jingye Gong, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Lijuan Pan, Qingyan Gao, Meng Jiao, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2024-212110

Published: 2024

Journal Articles

Clinical Characteristics of Long-Term Survivors Treated with BCMA CAR T Cell

Fangce WANG, Bing Li, Ping Li, Shiguang Ye, Lili Zhou, Wenjun Zhang, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6865.

https://doi.org/10.1182/blood-2023-185161

Published: 2023

Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6258.

https://doi.org/10.1182/blood-2023-180524

Published: 2023

Journal Articles

ITGB3 Promotes the Progression of JAK2V617F-Positive Myeloproliferative Neoplams By Regulating Calreticulin to Inhibit Cellular Autophagy

Jie Zhou, Wenjun Zhang, Baoqing Yang, Hao Wu, Bing Li, Shaoguang Li, Aibin Liang, Jianfei Fu

Blood (2023) 142 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2023-181816

Published: 2023

Journal Articles

U2AF1 S34F Mutation Promote Megakaryopoiesis and Fibrogenesis in MDS

Wenjun Zhang, Jinqin Liu, Lin Yang, Yiru Yan, Tiejun Qin, Zefeng Xu, Gang Huang, Bing Li, Zhijian Xiao

Blood (2023) 142 (Supplement 1): 5685.

https://doi.org/10.1182/blood-2023-185678

Published: 2023

Journal Articles

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms

Junying Wu, Yudi Zhang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Li Juan Pan, Robert Peter Gale, Bing Li, Zhijian Xiao

Blood (2023) 142 (Supplement 1): 1875.

https://doi.org/10.1182/blood-2023-184604

Published: 2023

Journal Articles

Unique Clinical Features and Mutation Profile in De Novo Myelodysplastic Syndromes with MF-1 and a Proposed Model for Distinguishing MDS with MF-2/3 from TN-PMF Based on Clinical and Genetic Covariates

Junying Wu, Wenjun Zhang, Peihong Zhang, Tiejun Qin, Zefeng Xu, Qi Sun, Yujiao Jia, Shiqiang Qu, Bing Li, Huijun Wang, Lijuan Pan, Jinqin Liu, Yudi Zhang, Xin Yan, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 4058–4059.

https://doi.org/10.1182/blood-2022-163019

Published: 2022

Journal Articles

Validation of the 5 th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute

Yudi Zhang, Junying Wu, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Lijuan Pan, Bing Li, Huijun Wang, Xin Yan, Jingye Gong, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 1343–1345.

https://doi.org/10.1182/blood-2022-160131

Published: 2022

Journal Articles

IPSS-M Is More Powerful for MDS Patients Older Than 60 Years Old

Junying Wu, Yudi Zhang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Lijuan Pan, Bing Li, Qingyan Gao, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 4092–4093.

https://doi.org/10.1182/blood-2022-165083

Published: 2022

Journal Articles

Mutational Landscape, Clonal Evolution and Prognostic Effect of Non-Driver Mutations during Disease Progression of Primary Myelofibrosis

Xin Yan, Zefeng Xu, Shiqiang Qu, Tiejun Qin, Gang Huang, Zhijian Xiao, Bing Li

Blood (2022) 140 (Supplement 1): 3965–3967.

https://doi.org/10.1182/blood-2022-165185

Published: 2022

Journal Articles

BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation

Bing Li, Wenbin An, Hua Wang, Timour Baslan, Shoron Mowla, Aishwarya Krishnan, Wenbin Xiao, Richard P. Koche, Ying Liu, Sheng F. Cai, Zhijian Xiao, Andriy Derkach, Ilaria Iacobucci, Charles G. Mullighan, Kristian Helin, Scott W. Lowe, Ross L. Levine, Raajit K. Rampal

Blood (2022) 139 (25): 3630–3646.

https://doi.org/10.1182/blood.2021014465

Published: 2022

Includes: Supplemental data

NARROW

CD38 Overexpressed Monocytes Play a Critical Role in the Fibrogenesis in Myeloproliferative Neoplasms and Can be Used As a Therapeutic Target to Ameliorate Fibrosis

The Implication of TP53 Allelic Status for Outcome and Erythropoiesis in MDS

GATA1 Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

Impact of the 15-Item Frailty Scale in IPSS-R/IPSS-M Subgroup of Patients (Pts) with Myelodysplastic Syndromes (MDS)

A Correlation of Ineffective Erythropoiesis and Dysregulated Pathways in Myelodysplastic Syndromes

Aberrant Splicing in CHEK1 Is a Driver of Megakaryocytic Dysplasia in U2AF1 S34F Mutant Myelodysplastic Syndromes

Construction and Verification of Prediction Model of Frailty Risk in Elderly Patients with Hematological Neoplasms

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

An Open-Label, Multicenter, Phase Ib Study of the Anti-TIM3 Monoclonal Antibody BC3402 in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Factors Associated with Progression to Overt Acute Myeloid Leukemia in NPM1 -Mutated Myeloid Neoplasms with Less Than 10% Blasts

Clinical Characteristics of Long-Term Survivors Treated with BCMA CAR T Cell

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ITGB3 Promotes the Progression of JAK2V617F-Positive Myeloproliferative Neoplams By Regulating Calreticulin to Inhibit Cellular Autophagy

U2AF1 S34F Mutation Promote Megakaryopoiesis and Fibrogenesis in MDS

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms

Unique Clinical Features and Mutation Profile in De Novo Myelodysplastic Syndromes with MF-1 and a Proposed Model for Distinguishing MDS with MF-2/3 from TN-PMF Based on Clinical and Genetic Covariates

Validation of the 5 th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute

IPSS-M Is More Powerful for MDS Patients Older Than 60 Years Old

Mutational Landscape, Clonal Evolution and Prognostic Effect of Non-Driver Mutations during Disease Progression of Primary Myelofibrosis

BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only